Evaluaciones económicas

Published on 15 de marzo de 2022 | http://doi.org/10.5867/medwave.2022.02.002118

Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru

Back to article Table 4.

Pharmaceutical and other benefit costs (US$) in in base scenario (Clínica Ricardo Palma) and Hospital Nacional Dos de Mayo scenario (US$).